GSTM1 and colorectal cancer: Emerging data has proven the utility of FIT in symptomatic patients with sensitivity and specificity reportedly ranging from 85 to 100% and 56 to 91% respectively for colorectal cancer detection at a threshold of ≥ 10 μg Hb/g faeces [8–15].